Uveitis associated with juvenile idiopathic arthritis and chronic idiopathic uveitis in children: A retrospective cohort study

Table 2 Main treatment outcomes in patients with juvenile idiopathic arthritis-associated uveitis and chronic idiopathic uveitis

Parameter	Juvenile idiopathic arthritis-associated uveitis (n = 68)	Chronic idiopathic uveitis (n = 28)	P value
Received MTX	57 (83.8)	27 (96.4)	0.171
Time to MTX prescription (years)			0.004
Mean	1.1	2.6
median (25%, 75%)	0.3 (0.1, 1.5)	0.8 (0.3, 7.2)
Min–max	0.0–8.4	0.0–11.4
Remission on MTX	39/55 (70.9)	13/23 (56.5)	0.293
Time to remission on MTX (years)			0.002
Mean	1.10	0.19
Median (25%, 75%)	0.30 (0.30, 0.60)	0.17 (0.08, 0.17)
Min–max	0.04–8.20	0.08–0.80
Flare on MTX	25/54 (46.3)	11/12 (91.7)	0.004
Time to first flare on MTX (years)			0.402
Mean	0.90	1.30
Median (25%, 75%)	0.60 (0.30, 1.10)	1.10 (0.30, 1.50)
Min–max	0.10–4.30	0.17–3.30
Biological treatment	44 (64.7)	23 (82.1)	0.141
Time since MTX to biologics (years)			0.593
Mean	1.5	2.0
Median (25%, 75%)	1.0 (0.4, 1.5)	1.1 (0.5, 3.0)
Min–max	0.3–4.8	0.2–7.0
Time before biological treatment (years)			0.020
Mean	2.3	4.4
Median (25%, 75%)	1.6 (0.6, 3.7)	3.2 (1.4, 7.2)
Min–max	0.0–8.0	0.3–12.5
Remission on biological treatment	35/45 (77.8)	19/20 (95.0)	0.151
Time to remission on biological treatment (years)			0.980
Mean	0.30	0.30
Median (25%, 75%)	0.20 (0.10, 0.40)	0.20 (0.10, 0.40)
Min–max	0.00–1.00	0.01–1.00
Flare on biological treatment	18/34 (52.9)	11/19 (57.9)	0.780
Time to first flare on biological treatment (years)			0.233
Mean	1.9	1.2
Median (25%, 75%)	1.6 (0.8, 2.5)	0.7 (0.3, 1.9)
Min–max	0.1–5.1	0.1–3.6
Received intraocular corticosteroid injections	32 (47.1)	18 (64.3)	0.177
Undergone surgery	18 (26.5)	7 (25.0)	1.0
Time to eye surgery (years)			0.796
Mean	4.5	5.0
Median (25%, 75%)	3.9 (1.3, 6.5)	4.5 (2.5, 5.2)
Min–max	0.1–10.7	1.3–12.5

Data are presented as n (%). Max: Maximum; Min: Minimum; MTX: Methotrexate.